Nigral degeneration and striatal dopaminergic dysfunction in idiopathic andparkin-linked Parkinson's disease

2005 ◽  
Vol 21 (3) ◽  
pp. 299-305 ◽  
Author(s):  
Michele T.M. Hu ◽  
Christoph Scherfler ◽  
Naheed L. Khan ◽  
Jo V. Hajnal ◽  
Andrew J. Lees ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Dysfunction ◽  
Nigral Degeneration

scholarly journals Respiratory changes in Parkinson's disease may be unrelated to dopaminergic dysfunction

2012 ◽  
Vol 70 (11) ◽  
pp. 847-851 ◽  
Author(s):  
Luciana Ulhôa Guedes ◽  
Juliana Melo Rodrigues ◽  
Aline Andrioni Fernandes ◽  
Francisco E. Cardoso ◽  
Verônica Franco Parreira
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Statistical Analysis ◽  
Healthy Controls ◽  
Maximal Inspiratory Pressure ◽  
Age And Gender ◽  
Dopaminergic Dysfunction ◽  
And Gender ◽  
Student’S T ◽  
Student’S T Test

OBJECTIVE: To investigate the maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) in patients with Parkinson's disease (PD) during the on and off periods of levodopa and to compare with healthy controls. METHODS: Twenty-six patients were analyzed with Hoehn and Yahr scores (2-3) and 26 age and gender matched-controls. Statistical analysis was performed with Student's t-test for paired and independent samples. RESULTS: MIP and MEP values in patients were significantly lower than the values obtained in controls both for off and on stages -excepted for MIP in women (p=0.28). For patients with PD, the studied parameters did not differ between stages on and off, with the exception of MEP in women (p=0.00). CONCLUSIONS: Patients with PD have respiratory pressure lower than controls, even in early stages of the disease, and dopamine replacement has little impact over these respiratory pressures. These findings suggest that respiratory changes in PD may be unrelated to dopaminergic dysfunction.

scholarly journals In vivodetection of lateral-ventral tier nigral degeneration in Parkinson's disease

2017 ◽  
Vol 38 (5) ◽  
pp. 2627-2634 ◽  
Author(s):  
Daniel E. Huddleston ◽  
Jason Langley ◽  
Jan Sedlacik ◽  
Kai Boelmans ◽  
Stewart A. Factor ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nigral Degeneration

Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease

2017 ◽  
Vol 37 ◽  
pp. 106-110 ◽  
Author(s):  
Marina Picillo ◽  
Gabriella Santangelo ◽  
Roberto Erro ◽  
Autilia Cozzolino ◽  
Marianna Amboni ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
De Novo ◽  
Dopaminergic Dysfunction

Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell

2001 ◽  
Vol 50 (1) ◽  
pp. 34-41 ◽  
Author(s):  
Henk W. Berendse ◽  
Jan Booij ◽  
Chantal M. J. E. Francot ◽  
Paul L. M. Bergmans ◽  
Ron Hijman ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Sense Of Smell ◽  
Dopaminergic Dysfunction

scholarly journals Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?

2015 ◽  
Vol 87 (6) ◽  
pp. 633-641 ◽  
Author(s):  
Helen Ling ◽  
Seamus Kearney ◽  
Helen Lai Kuen Yip ◽  
Laura Silveira-Moriyama ◽  
Tamas Revesz ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nigral Degeneration

scholarly journals The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies

2021 ◽  
Vol 11 (12) ◽  
pp. 1573
Author(s):  
Samay Prakash ◽  
Wayne G. Carter
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Unmet Need ◽  
Neuroprotective Agents ◽  
Eligibility Criteria ◽  
Neuroprotective Effects ◽  
In Vivo Models ◽  
Anti Inflammatory ◽  
Nigral Degeneration

Currently, there are no pharmacological treatments able to reverse nigral degeneration in Parkinson’s disease (PD), hence the unmet need for the provision of neuroprotective agents. Cannabis-derived phytocannabinoids (CDCs) and resveratrol (RSV) may be useful neuroprotective agents for PD due to their anti-oxidative and anti-inflammatory properties. To evaluate this, we undertook a systematic review of the scientific literature to assess the neuroprotective effects of CDCs and RSV treatments in pre-clinical in vivo animal models of PD. The literature databases MEDLINE, EMBASE, PsychINFO, PubMed, and Web of Science core collection were systematically searched to cover relevant studies. A total of 1034 publications were analyzed, of which 18 met the eligibility criteria for this review. Collectively, the majority of PD rodent studies demonstrated that treatment with CDCs or RSV produced a significant improvement in motor function and mitigated the loss of dopaminergic neurons. Biochemical analysis of rodent brain tissue suggested that neuroprotection was mediated by anti-oxidative, anti-inflammatory, and anti-apoptotic mechanisms. This review highlights the neuroprotective potential of CDCs and RSV for in vivo models of PD and therefore suggests their potential translation to human clinical trials to either ameliorate PD progression and/or be implemented as a prophylactic means to reduce the risk of development of PD.

Sign in / Sign up

Export Citation Format

Share Document